Obesity specialist Beverly Tchang posts her top three takeaways on the science of amylin based drugs after speaking at an AAFP event.
Recap by typeshit. Post by Beverly G. Tchang, MD on X.
A new GLP-1 described as stronger than current options is being tested in trials, and researchers lay out what people should understand about it.
Among 208,970 matched adults with type 2 diabetes, GLP-1 starters had 0.15% new diagnoses versus 0.10% on DPP-4 drugs. Authors call it a signal needing confirmation.
Researchers used AI to identify fungal peptides that taste salty or boost saltiness, aimed at cutting sodium in food. A food science find rather than a drug story.
The 1,200-person trial starts next year with MIT and Pitt researchers, funded by a $13 million Arnold Ventures grant, and will also track housing and jobs.
MedPage Today
A JAMA Network Open analysis of Reddit posts also lists fatigue, insomnia and muscle symptoms. MedPage's roundup adds a CagriSema menopause analysis and Walmart's GLP-1 coverage plan.
Longevity Technology reports BodySpec's new offering targets GLP-1 users worried about muscle, with body scans said to take about 12 minutes.
Loading…